ROTH Capital Partners Announces the Promotion of Yasmeen Rahimi, Ph.D.

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–ROTH Capital Partners (“ROTH”), www.roth.com,
a full service investment bank focused on serving emerging growth
companies and their investors, today announced that Yasmeen Rahimi,
Ph.D., Managing Director and Senior Research Analyst, has been promoted
to the role of Co-Head of Biotechnology Research.

Yasmeen has been a Senior Research Analyst at ROTH since 2017, covering
companies that are developing therapeutics to treat various liver
diseases and conditions, including Nonalcoholic Steatohepatitis (NASH).
She also covers companies that are developing products aligned in the
orphan and ultra-orphan therapeutics, as well as women’s health.

Dr. Rahimi has extensive expertise in NASH and liver metabolism with 16
publications in highly prestigious journals. She trained at Yale
University in the laboratory of Dr. Gerald Shulman, a world-renowned
endocrinologist who pioneered the understanding of lipid-induced insulin
resistance. In addition, she completed her Ph.D. training in the
laboratory of Dr. Robert A. Harris, a distinguished biochemist at
Indiana University.

Jeff Martin, CFA, Director of Research, commented, “I am pleased to have
Dr. Rahimi and Dr. Tony Butler leading our biotech research effort. We
have made a commitment of resources to the sector, to support the
companies making the scientific advancements that will help find cures
and treatments for some of the most debilitating diseases.”

Dr. Rahimi stated, “I am grateful to ROTH for this promotion and
continued investment in fostering innovation and creativity in
healthcare. I look forward to working with my fellow research analysts
and associates and the entire ROTH team to create impactful and
specially designed research across various therapeutics areas.”

“Dr. Rahimi has demonstrated passion, credibility, and initiative to
promote the ROTH healthcare practice that is rare for a person with her
relatively few years of experience,” said Byron Roth, CEO of ROTH
Capital Partners. “She has earned this promotion, and we look forward to
working with her for years to come.”

Since 2010, ROTH has completed over 400 transactions for healthcare
companies, raising over $16 billion in growth capital. (Source: ROTH
Capital Partners – 03/27/2019).

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment
bank focused on serving emerging growth companies and their investors.
As a full-service investment bank, ROTH provides capital raising, M&A
advisory, analytical research, trading, market-making services and
corporate access. Headquartered in Newport Beach, Calif., ROTH is
privately-held and owned by its employees, and maintains offices
throughout the U.S. For more information on ROTH, please visit www.roth.com.

Contacts

Investor and Media Contact:
ROTH Capital Partners
Isabel
Mattson-Pain, Director of Marketing
[email protected]
949-720-7117